Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Depreciation and Depletion: 2022-2023

Historic Depreciation and Depletion for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Sep 2023 value amounting to $100,000.

  • Phathom Pharmaceuticals' Depreciation and Depletion fell 50.00% to $100,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $400,000, marking a year-over-year change of. This contributed to the annual value of $600,000 for FY2022, which is 20.00% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Depreciation and Depletion of $100,000 as of Q3 2023, which was down 0.00% from $100,000 recorded in Q2 2023.
  • In the past 5 years, Phathom Pharmaceuticals' Depreciation and Depletion registered a high of $200,000 during Q3 2022, and its lowest value of $100,000 during Q1 2022.
  • Its 2-year average for Depreciation and Depletion is $114,286, with a median of $100,000 in 2023.
  • Data for Phathom Pharmaceuticals' Depreciation and Depletion shows a maximum YoY plummeted of 50.00% (in 2023) over the last 5 years.
  • Over the past 2 years, Phathom Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $100,000 in 2022, then plummeted by 50.00% to $100,000 in 2023.
  • Its last three reported values are $100,000 in Q3 2023, $100,000 for Q2 2023, and $100,000 during Q1 2023.